Immunome Set to Release Q4 2025 Earnings as Analysts Adjust Ratings

Immunome (NASDAQ: IMNM) is expected to announce its Q4 2025 earnings on Wednesday, March 18, 2025, before the market opens. Analysts predict the company will report a loss of ($0.64) per share, alongside revenue of $0.785 million for the quarter. Investors can access the company’s earnings summary and details about the earnings call scheduled for March 3, 2026, at 15:00 ET.

In its last earnings report on March 3, 2025, Immunome revealed a loss of ($0.75) per share, falling short of analysts’ expectations of ($0.65) by ($0.10). The company has struggled with a negative return on equity of 57.61% and a significant net margin of (1,687.08%). Analysts forecast an average loss of ($2) per share for the current fiscal year, with projections of ($3) per share for the next fiscal year.

Immunome’s stock opened at $20.36 on Monday, reflecting a decrease of 3.0%. The company boasts a market capitalization of $2.30 billion and a price-to-earnings ratio of (8.41), with a beta of 2.12. The 50-day moving average for Immunome is $22.73, while the 200-day moving average stands at $18.18. Over the past year, the stock has fluctuated between a low of $5.15 and a high of $27.65.

Institutional Activity and Analyst Ratings

Recent trading activity shows several institutional investors and hedge funds adjusting their positions in Immunome. T. Rowe Price Investment Management Inc. increased its holdings by 59.4% in the fourth quarter, now owning 13,421,987 shares valued at approximately $288.3 million. Invesco Ltd. raised its stake by an impressive 382.1%, acquiring an additional 214,049 shares to hold 270,065 shares worth $5.8 million.

Additionally, Virtus Investment Advisers LLC and Wellington Management Group LLP made significant increases in their holdings, raising stakes by 16.9% and 267.8%, respectively. Currently, institutional investors and hedge funds hold 44.58% of Immunome’s stock.

Analysts have recently updated their ratings on Immunome’s stock. Evercore raised its price target from $18.00 to $40.00, giving the stock an “outperform” rating. Conversely, Wall Street Zen downgraded it from “hold” to “sell” on March 7, 2025. Lake Street Capital also increased its target price from $22.00 to $32.00, maintaining a “buy” rating. Craig Hallum revised its target from $33.00 to $36.00, also rating it as a “buy.” According to MarketBeat, the overall consensus among analysts is a “Moderate Buy” with an average price target of $33.45.

About Immunome

Immunome, Inc. is a clinical-stage biotechnology firm specializing in the discovery and development of innovative antibody-based therapies targeting oncology and infectious diseases. The company utilizes a proprietary platform to explore the natural B-cell repertoire of patients with active diseases, aiming to identify fully human monoclonal antibodies with unique mechanisms of action. This approach seeks to reveal antibodies that engage the immune system in novel ways, potentially leading to therapies with enhanced efficacy and safety profiles.

Immunome’s primary oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials aimed at breast cancer antigens. As the company prepares for its upcoming earnings announcement, investors and analysts will be closely monitoring its progress and market response.